Karyopharm Therapeutics reported $358.17M in Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Amgen AMGN:US USD 65.12B 1.42B
AstraZeneca AZN:LN USD 96.48B 2.3B
Astrazeneca AZN:US USD 96.48B 2.3B
Avrobio Inc AVRO:US USD 129.5M 16.75M
Biocryst Pharmaceuticals BCRX:US USD 550M 8.59M
Enanta Pharmaceuticals ENTA:US USD 347.53M 27.88M
GlaxoSmithKline GSK:LN GBP 60.15B 167M
Karyopharm Therapeutics KPTI:US USD 358.17M 126.94M
Macrogenics MGNX:US USD 280.47M 85.12M
Mirati Therapeutics MRTX:US USD 1.2B 100.44M
Nektar Therapeutics NKTR:US USD 710.6M 70.41M
Novartis NOVN:VX USD 117.45B 1.01B
Novartis NVS:US USD 117.45B 1.01B
Regeneron Pharmaceuticals REGN:US USD 29.21B 1.54B
Roche Holding ROG:VX 88.15B 1.42B
Sangamo Biosciences SGMO:US USD 562.51M 31.4M
Takeda 4502:JP JPY 13.5T 1.08T
Tg Therapeutics TGTX:US USD 193.57M 24.32M
Ultragenyx Pharmaceutical RARE:US USD 1.55B 73.03M
Xencor XNCR:US USD 846.27M 11M
YTE INCY:US USD 5.84B 330.77M